Document Detail

Risk of hypothyroidism in patients with cancer treated with sunitinib: A systematic review and meta-analysis.
MedLine Citation:
PMID:  23282114     Owner:  NLM     Status:  Publisher    
Background. The multitargeted tyrosine kinase inhibitor sunitinib is used in various cancers. Clinical studies have reported a substantial variation in the incidence of hypothyroidism associated with sunitinib, without a systemic attempt to synthesize these data. Methods. We searched Medline databases for relevant clinical trials published up to May 2012. Phase II and III trials and expanded access programs of sunitinib in patients with any type of cancer that reported occurrence of hypothyroidism were eligible. The summary incidence, relative risk (RR) and 95% confidence intervals (CIs) were calculated using random- or fixed-effects models based on the heterogeneity of included studies. Results. Incidence analysis was performed using 6678 sunitinib-treated patients from all 24 eligible trials. The incidence of all- and high-grade hypothyroidism was 9.8% (95% CI 7.3-12.4%) and 0.4% (95% CI 0.3-0.5%), respectively. A meta-analysis of seven randomized trials with 2787 subjects revealed a RR of all- and high-grade hypothyroidism of 13.95 (95% CI 6.91-28.15; p < 0.00001) and 4.78 (95% CI 1.09-20.84; p = 0.04), respectively. Subgroup analysis revealed a significantly higher incidence of all-grade hypothyroidism in patients receiving sunitinib for longer duration than in patients receiving sunitinib for shorter duration (p = 0.02). Conclusions. This meta-analysis of data available from clinical trials demonstrates that sunitinib is associated with a significant risk of developing all- and high-grade hypothyroidism. These data provide further evidence to recommend monitoring for hypothyroidism in patients receiving sunitinib.
Tomohiro Funakoshi; Yuichi J Shimada
Related Documents :
24813714 - Malaria prevention in the pregnant traveller: a review.
25022164 - Mortality among soviet and russian cosmonauts: 1960-2013.
23537114 - Sex-specific risk of cardiovascular disease and cognitive decline: pregnancy and menopa...
24289624 - Determining the knowledge of women and their attitudes regarding gynecological cancer p...
17468794 - Benefit of outpatient cardiac rehabilitation in under-represented patient subgroups.
24355704 - Blood, sex and trust: the limits of the population-based risk management paradigm.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2013-1-3
Journal Detail:
Title:  Acta oncologica (Stockholm, Sweden)     Volume:  -     ISSN:  1651-226X     ISO Abbreviation:  Acta Oncol     Publication Date:  2013 Jan 
Date Detail:
Created Date:  2013-1-3     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8709065     Medline TA:  Acta Oncol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Department of Medicine, Beth Israel Medical Center, University Hospital and Manhattan Campus for the Albert Einstein College of Medicine , New York , USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Effect of mindfulness-based stress reduction on sleep quality: Results of a randomized trial among D...
Next Document:  Affiliation to the work market after curative treatment of head-and-neck cancer: A population-based ...